...
首页> 外文期刊>The Australian and New Zealand journal of psychiatry >Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
【24h】

Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.

机译:双重动作?结合文拉法辛和米氮平治疗抑郁症。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Venlafaxine and mirtazapine in combination are increasingly used in clinical practice to treat treatment-refractory depression. Putative efficacy for this combination of antidepressants, beyond that of monotherapy, stems from their synergistic actions. This paper describes a prospective case series that examined the efficacy of the venlafaxine-mirtazapine combination in the treatment of depressed patients who had failed at least one antidepressant trial. METHOD: Twenty-two depressed patients with major depression were treated with venlafaxine and mirtazapine in combination for an average of just under 8 weeks. Baseline ratings on the 17-item Hamilton Depression Rating Scale (HAM-D(17)), Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression-Severity Scale (CGI-S) were repeated at end-point, determined by the naturalistic termination of the depressive treatment episode or the discontinuation of the combination treatment due to adverse effects. The length of treatment until end-point was documented for each patient. Descriptive statistics were used on the collated data. RESULTS: At baseline, mean scores were 28.8 (SD=3.8) for HAM-D(17), 30.1 (SD=5.8) for MADRS, and 4.5 (SD=0.5) for CGI-S, reflecting a cohort at the moderate to severe end of the spectrum. At end-point, mean absolute scores were 10.2 (SD=4.7) for HAM-D(17), 10.8 (SD=4.6) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean change from baseline was 18.6 (SD=6.4) for HAM-D(17), 19.3 (SD=6.8) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean duration of treatment was approximately 8 weeks, producing a response rate of 81.8% and a remission rate of 27.3%. Only one patient was unable to tolerate the combination although nearly half (10) had significant side-effects during treatment. CONCLUSION: This study demonstrates relatively high response and remission rates that are encouraging and contribute to the efficacy database for this antidepressant combination. Further studies using randomized controlled designs are needed.
机译:目的:文拉法辛与米氮平联用在临床上越来越多地用于治疗难治性抑郁症。除单一疗法外,这种抗抑郁药组合的推定功效源于它们的协同作用。本文描述了一个前瞻性病例系列,该系列研究了文拉法辛-米氮平组合在治疗至少一项抗抑郁试验失败的抑郁症患者中的疗效。方法:将22例重度抑郁症的抑郁症患者接受文拉法辛和米氮平联合治疗,平均间隔不到8周。确定终点时重复进行17个项目的汉密尔顿抑郁量表(HAM-D(17)),蒙哥马利-阿斯伯格抑郁量表(MADRS)和临床总体印象严重度量表(CGI-S)的基线量表。通过自然终止抑郁治疗或因不良反应而终止联合治疗。记录每位患者直至终点的治疗时间。描述性统计数据用于整理后的数据。结果:基线时,HAM-D(17)的平均得分为28.8(SD = 3.8),MADRS的平均得分为30.1(SD = 5.8),CGI-S的平均得分为4.5(SD = 0.5),反映了中度至中等严重的结束。最终,HAM-D(17)的平均绝对得分为10.2(SD = 4.7),MADRS的平均绝对得分为10.8(SD = 4.6),CGI-S的平均得分为2.3(SD = 0.6)。 HAM-D(17)从基线的平均变化为18.6(SD = 6.4),MADRS为19.3(SD = 6.8),CGI-S为2.3(SD = 0.6)。平均治疗时间约为8周,缓解率为81.8%,缓解率为27.3%。尽管近一半(10)在治疗期间有明显的副作用,但只有一名患者无法耐受该组合。结论:本研究表明相对较高的缓解率和缓解率令人鼓舞,并有助于该抗抑郁药组合的疗效数据库。需要使用随机对照设计进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号